Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deciphera Pharmaceuticals
Biotech
Ono’s Deciphera drops early-stage solid tumor drug
Ono said the pan-RAF inhibitor has been scrapped for reasons unrelated to safety or efficacy.
Darren Incorvaia
Mar 3, 2026 7:47pm
Deciphera's tumor-tackling oral med achieves 40% response rate
Oct 30, 2023 11:00am
Mirati CEO exits—Chutes & Ladders
Aug 11, 2023 9:30am
Deciphera nabs speedy review for GIST cancer hopeful
Feb 13, 2020 7:32am
Deciphera files for approval of cancer drug ahead of schedule
Dec 16, 2019 8:20am
Deciphera soars as phase 3 cancer data tee up FDA filing
Aug 13, 2019 8:39am
